Dermatology

Flyer for Pemphigus Foliaceus Clinical Trial in Dogs

Select for Larger Image

Below, please find links to all of the clinical trials involving dermatology. The studies include a multitude of information, including (but not limited to) the study’s purpose, benefits for participating, and financial incentive information. If you have any questions, please contact the individual outlined at the end of each trial summary.

Please visit the Dermatology service webpage at the Veterinary Medical Teaching Hospital (VMTH) if you would like to learn more about the amazing things that our veterinarians can do for you and your animal.

Dogs

Pemphigus Foliaceus: Finding a New Treatment

Title: A Pilot Study of the Efficacy of a Bruton’s Tyrosine Kinase Inhibitor (BTKi) in the Treatment of Dogs with Pemphigus Foliaceus (PF)

Purpose of Study: Although it is a rare skin disease, pemphigus foliaceus (PF) is the most common form of pemphigus and probably the most common cutaneous autoimmune disease in the dog. The goal of this study is to assess the efficacy of a Bruton’s Tyrosine Kinase inhibitor (BTKi) as a therapy for canine pemphigus foliaceus (as pills which can also be crushed into powder in food if necessary).

Contact: Call the Dermatology Office at (530) 754-5908 or email Dr. Stephen White (sdwhite@ucdavis.edu) or Dr. Catherine Outerbridge (caouterbridge@ucdavis.edu)

Participation Requirements: Dogs weighing over 15 pounds (6.8 kilograms) that are suspected of having or have been previously diagnosed with Pemphigus Foliaceus

Initial Evaluation for Participation: None.

Procedures: We will collect a punch skin biopsy (using a local anesthetic and under sedation if needed) or review the histopathology report of a previously collected biopsy to confirm PF diagnosis. If the biopsy test results have confirmed the diagnosis of PF and you agree to let your dog participate in this study, the following will happen:

  • Day 1: We will perform a physical examination, collect a blood and urine sample to confirm no abnormalities, and take photographs of the lesions. This visit will require a serial blood draw to examine the drug levels in the body over a 24-hour period after the administration of one dose of the BTKi, which means that you will need to leave your dog at the VMTH for up to two nights.
  • Weeks 2, 4, 8, 12, 16, 20: We will perform a physical examination, collect a blood and/or urine sample, and take photographs of the lesions. No overnight stay required.

Benefits: If the initial skin biopsy confirms the diagnosis of pemphigus foliaceus, the sponsor will pay for the cost of the skin biopsy and the office visit (as a credit to your account), and cover all other costs associated with this study as well as any expenses incurred as a result of adverse reactions to the experimental drug (up to $4800). Additionally, upon completion, you will be compensated $200 for taking part in this study.

We cannot promise any benefits to your dog or other animals from your taking part in this clinical trial; however, possible benefits include control of your dog’s PF while on the drug. Additionally, we hope to get a general understanding of the benefit of this drug and others closely related to it in dogs with PF and similar diseases.

Owner Responsibilities: We expect that participation in this clinical trial will last for 20 weeks. You will need to bring your dog in to scheduled appointments every week for the first month (except Week 3) and then every month after that for the next four (4) months. Additionally, you will need to give your dog the prescribed drug as instructed by the Dermatology Service at the UC Davis Veterinary Medical Teaching Hospital.

If the diagnosis is not confirmed, you will be responsible for the cost of the skin biopsy and the office visit. For more information about possible costs, please contact the investigator.

Printable Flyer (PDF)
Printable Flyer for Bearded Collies (PDF)